XML 30 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) $ 355,757 $ (158,267) $ (48,169)
Adjustments to reconcile net income (loss) to cash flows from operating activities:      
Depreciation and amortization 74,927 77,862 78,652
Share-based compensation expense 100,905 94,254 87,622
Deferred income taxes (99,902) (32,795) 5,081
Change in the fair value of contingent consideration   21,750 1,427
Other non-cash charges 6,329 5,531 2,650
Changes in assets and liabilities:      
Receivables (44,510) 25,250 (38,011)
Contract assets 8,223 4,434 6,037
Inventory (2,712) (31,021) (24,769)
Prepaid expenses and other assets (34,847) (5,328) 11,481
Right-of-use assets 15,387 16,569 17,051
Accounts payable and accrued expenses 23,009 15,534 11,514
Accrued sales discounts, allowances and reserves 11,526 14,899 18,339
Contract liabilities (5,926) (7,129) (6,080)
Operating lease liabilities (16,147) (33,225) (16,777)
Other long-term liabilities 9,334 12,726 (4,333)
Cash flows provided by operating activities 401,353 21,044 101,715
CASH FLOWS FROM INVESTING ACTIVITIES:      
Additions of property, plant and equipment (48,048) (38,255) (28,020)
Proceeds from the sale of equipment 354   287
Proceeds from contingent consideration   1,273 7,937
Return of Fountain Healthcare Partners II, L.P. investment   485  
Payment made for licensed Intellectual Property ("IP")     (1,000)
Purchases of investments (254,471) (309,671) (340,418)
Sales and maturities of investments 355,522 281,627 295,010
Cash flows provided by (used in) investing activities 53,357 (64,541) (66,204)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Cash transferred to Mural Oncology plc at separation (275,000)    
Proceeds from the issuance of ordinary shares under share-based compensation arrangements 16,760 19,630 25,319
Employee taxes paid related to net share settlement of equity awards (28,474) (18,204) (16,571)
Proceeds from the issuance of long-term debt     23,567
Payment made for debt extinguishment     (993)
Principal payments of long-term debt (3,000) (3,000) (2,250)
Cash flows (used in) provided by financing activities (289,714) (1,574) 29,072
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 164,996 (45,071) 64,583
CASH AND CASH EQUIVALENTS—Beginning of period 292,473 337,544 272,961
CASH AND CASH EQUIVALENTS—End of period 457,469 292,473 337,544
SUPPLEMENTAL CASH FLOW DISCLOSURE:      
Cash paid for interest 22,748 13,563 6,904
Cash paid for taxes 44,243 20,749 1,888
Non-cash investing and financing activities:      
Purchased capital expenditures included in accounts payable and accrued expenses $ 2,645 $ 2,950 $ 6,025